Working Groups

Between 30 and 44 percent of Germans are infected with the bacterium Helicobacter pylori. Even if no symptoms occur, such an infection can increase the long-term risk of developing stomach cancer. Due to an increase in primary antibiotic resistance, therapy must be tailored precisely to avoid ...

Mark Brönstrup’s research group aims to identify and optimize new antibacterial and antiviral agents. They therefore test collections of various compounds using newly developed assay systems and are expanding the DZIF infrastructure in collaboration with the European network EU OPENSCREEN. In ...

The imaging platform in Heidelberg offers scientists the most up-to-date microscopes and imaging techniques. It enables the observation of pathogenic processes both in complex tissues and in vivo. This platform was designed to accommodate biosafety levels BSL 2 and 3, both of which are important for ...

When emerging viruses cause severe diseases, the rapid development of vaccines and antivirals against these pathogens becomes critical. Some newly emerging viruses are very dangerous and necessitate the highest of biosafety levels for research and development purposes. DZIF scientists have a ...

The Clinical and Ambulant Study Center (CLASTER) supports the planning and implementation of clinical and epidemiological studies within the DZIF research area "Community-Acquired Infections at Mucosal Interfaces". Its mission is to accelerate the translation of discoveries from basic research into ...

This research group, led by Professor Marylyn Addo, initiates and coordinates translational research in the field of emerging infections with a particular focus on Ebola, MERS, Lassa and Crimean-Congo haemorrhagic fever. Immunology studies, vaccine development, testing of novel anti-infectives and ...

The CERMEL (Centre de Recherche Médical de Lambaréné) in Gabon is one of the leading establishments for malaria research in Africa. Clinical trials on vaccines and agents are tested according to the same approved guidelines that are used in Germany. A clinical research group was established within ...

The Clinical Research Unit (CRU) at Tübingen University Hospital, headed by Christoph Stein-Thoeringer, combines expertise from the fields of clinical medicine, infectious diseases, microbiome research, immunology, basic sciences, and epidemiology. Scientists and physicians collaborate closely to ...

The Clinical Trials Platform at the Tübingen Institute of Tropical Medicine supports the development of new agents and vaccines against infectious diseases. It focuses on conducting experimental studies and first trials on humans. A special feature is the human malaria infection model, developed in ...

The Clinical Tuberculosis Center provides the expertise and infrastructure for the optimization, prevention, diagnosis, and treatment of tuberculosis (TB) as well as for translating research results into clinical practice. The main objectives of the Clinical Tuberculosis Center include coordinating ...